Skip to main content
Fig. 10 | BMC Cancer

Fig. 10

From: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma

Fig. 10

a Evaluation of the sensitivity of chemotherapy drugs between the high-risk and low-risk groups based on the IC50 values of paclitaxel, cisplatin and doxorubicin for EC patients. b Differences in molecular drug sensitivity between the high-risk and low-risk groups based on IC50 values of AKT inhibitor VIII, VEGFR inhibitor (pazopanib) and mTOR inhibitor (temsirolimus)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us